Matthew Brams - 09 Mar 2026 Form 4 Insider Report for Cingulate Inc. (CING)

Reporting relationship: EVP and Chief Medical Officer
Issuer ticker: CING
Reported as of: 09 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 11 Mar 2026, 20:13:25 UTC
Prior SEC filing: 10 Feb 2026
Next SEC filing: 20 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Shane J. Schaffer, Attorney-in-Fact

Key filing fact

Matthew Brams filed Form 4 for Cingulate Inc. (CING) on 11 Mar 2026.

Key facts

This page summarizes Matthew Brams's Form 4 filing for Cingulate Inc. (CING).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 11 Mar 2026, 20:13.

Change

Previous filing in this sequence was filed on 10 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001884361 Primary reporting owner

Brams Matthew

Relationship: EVP and Chief Medical Officer
Address: 1901 W. 47TH PLACE, KANSAS CITY
Signature: /s/ Shane J. Schaffer, Attorney-in-Fact
Signature date: 11 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CING transaction

Common Stock

Award

Transaction value
Shares: +4,526
Change %: +97%
Price: $0.000000^*
Shares after: 9,182
Date: 09 Mar 2026
Ownership: Direct
Footnotes: F1

CING transaction

Common Stock

Tax liability

Transaction value
Shares: -1,025
Change %: -11%
Price: $0.000000^*
Shares after: 8,157
Date: 09 Mar 2026
Ownership: Direct
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Shares of common stock were granted pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended, for a portion of the Reporting Person's 2025 bonus.

Footnote F2

Shares otherwise issuable were withheld to satisfy the Reporting Person's tax obligations on the grant described in footnote 1 above.